News Releases

Date Title and Summary Additional Formats
Toggle Summary HTG Edge System Wins 2013 Silver Medical Design Excellence Award
TUCSON, Ariz. (June, 2013) – The Edge System, developed and commercialized by HTG Molecular Diagnostics, is the 2013 Silver Award recipient for in-Vitro Diagnostics in the 15th Annual Medical Design Excellence Awards competition. The HTG Edge System is the only automated RNA analysis platform that
View HTML
Toggle Summary HTG Molecular Diagnostics Edge System a Finalist for Medical Design Excellence Award
TUCSON, Ariz. (April, 2013) –The Edge System, developed by HTG Molecular Diagnostics, is a finalist in the 15th Annual Medical Design Excellence Awards competition. HTG Molecular Diagnostics is a privately held company specializing in RNA based diagnostics and solutions for translational research.
View HTML
Toggle Summary HTG Molecular Diagnostics and PROOF Centre Partner to Commercialize COPD Prognostic Test
TUCSON, Ariz. (November 27, 2012) – The Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) and HTG Molecular Diagnostics have finalized a license agreement that provides HTG Molecular Diagnostics exclusive rights to commercialize PROOF Centre-developed gene expression blood
View HTML
Toggle Summary HTG Molecular Diagnostics Introduces the EDGE System at AMP Conference
TUCSON, Ariz. (October 18, 2012) – HTG Molecular Diagnostics will unveil the EDGE system at the AMP conference in Long Beach, October 25 – 27, 2012. The EDGE system is the first fully-automated instrumentation designed for clinical and research laboratories that offers nucleic acid extraction-free
View HTML
Toggle Summary HTG Molecular Diagnostics Hires Novartis Veteran as VP Translational Science and Chief Medical Officer
TUCSON, Ariz. (September 13, 2012) – HTG Molecular Diagnostics, a privately-held, Tucson-based provider of molecular-technology solutions, hired Vijay Modur, M.D., Ph.D. as vice president of translational science and chief medical officer. Dr. Modur joins HTG Molecular Diagnostics from Novartis
View HTML
Toggle Summary HTG Molecular Diagnostics Achieves ISO 13485:2003 Certification
Demonstrating Internationally Recognized Standards for Quality Management in Provision of Medical Devices and Related Services TUCSON, Ariz. (July 30, 2012) – HTG Molecular Diagnostics, a privately-held company providing products for gene expression profiling, has achieved ISO 13485:2003
View HTML
Toggle Summary HTG Molecular Diagnostics Licenses Breast Cancer Marker Patent Portfolio from Merck
TUCSON, Ariz. (July 11, 2012) – HTG Molecular Diagnostics, a privately held, Tucson-based developer of mRNA and miRNA gene expression-based cancer diagnostics, has been granted a non-exclusive license to develop, manufacture, and commercialize breast cancer diagnostic tests under Merck’s patent
View HTML
Toggle Summary HTG Molecular Diagnostics Hires Vice President of Molecular Diagnostic Sales
TUCSON, Ariz. (June, 2012) – HTG Molecular Diagnostics, a privately-held, Tucson-based provider of molecular-technology solutions, hired Steve Hagan as vice president of molecular diagnostic sales. Hagan joins HTG Molecular Diagnostics from Ventana Medical Systems, a member of the Roche group,
View HTML
Toggle Summary HTG Molecular Diagnostics Partners with John Wayne Cancer Institute to Commercialize Melanoma Signatures
TUCSON, Ariz. (June 1, 2012) – The John Wayne Cancer Institute (JWCI) at Saint John’s Health Center in Santa Monica, California selected HTG Molecular Diagnostics as an exclusive commercialization partner for recently identified HTG melanoma signature assays which may be useful for diagnostic and
View HTML
Toggle Summary Sam Rua HTG Molecular Diagnostics VP of Regulatory Affairs is Keynote Presenter at TIDES Conference
TUCSON, Ariz. (May 14, 2012) – Sam Rua, vice president of regulatory affairs and quality systems at HTG Molecular Diagnostics, will offer a keynote presentation, “Update on Commercialization of RUO and IUO Products and Oversight of Lab-Developed Tests,” at the 2012 TIDES Oligonucleotide and Peptide
View HTML